What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?
After participating in this webinar, viewers should be able to:
- Explain what the key drivers are when selecting RRMM patients for treatment with bispecific antibodies
- Michel Delforge (Belgium)
- Paula Rodriguez-Otero (Spain)
- Philippe Moreau (France)